RE: Avct v quidel14 Jun 2020 15:31
From Turner and pope research paper:
The most efficient and simplest to use, early to market solution supported by comprehensive international distribution will likely capture the greatest slice of the commercial opportunity. Avacta appears positioned to secure this crown, having in addition also announced a collaboration with Adeptrix (Beverly, MA, USA) to develop and manufacture an Affimer®-based BAMS™ (bead-assisted mass spectrometry) coronavirus antigen test that will provide clinicians with a significant expansion of the available testing capacity for COVID-19 infection in hospitals. Presently there is only one other ‘nasal swab’ FDA-approved antigen test (from Quidel Corp), yet it appears to be somewhat flawed due to relatively (85%) poor detection sensitivity and is something which Avacta’s codeveloped product is expected to surpass.
From this point, timing is clearly key. There are presently only a few rapid antigen tests in development and, as yet, none have CE/FDA approval. In anticipation of quick development and subsequent approval, Avacta has already put in place one distribution partner, Medusa19, for the direct-to-consumer market and will put in place additional distribution partners for the healthcare professional/work-force testing markets, as well as OEM partnerships in order to maximise the commercial opportunity for the Affimer reagents it has developed that detect the coronavirus. Avacta intends to further commercialise the COVID-19 Affimer® reagents that it has generated through additional diagnostic development partnerships
Sign In
Follow the stocks
